The management of schizophrenia: focus on extended-release quetiapine fumarate

摘要: Effective management of schizophrenia remains a significant clinical challenge. While antipsychotic medications have proven efficacy in this disease, there an opportunity to further improve symptom control and long-term relapse prevention. Also, number factors, including tolerability complex dosing regimens, can result nonadherence medication. Quetiapine is atypical with established profile schizophrenia. The once-daily extended-release formulation (quetiapine XR) offers simplified regimen titration schedule. Short-term studies shown that quetiapine XR (400-800 mg/d) efficacious the acute treatment schizophrenia, while study has was significantly more effective than placebo at preventing relapse. Furthermore, investigation which stable patients switched from immediate-release IR) showed generally well tolerated no loss compared IR. In who experienced insufficient or poor on their previous antipsychotic, switching improved treatment. conclusion, for may patient adherence, impact positively outcomes.